摘要
近年来,运用纳米制剂靶向技术治疗癌症取得了很好的疗效,尤其是共递送多种抗癌药物。相比单一药物,联合应用不同药物分子靶向治疗范围更广,能有效地降低药物的毒副作用,或是相同细胞通路的抗癌药物组合疗法,减少每种药物剂量并增强疗效,均可能在一定程度上逆转多药耐药性。但是,组合给药因不同药物的药代动力学差异导致药物摄取不一致而受到限制,而且疗效与组合药物的相对浓度关系密切,一定比例的药物组合产生协同作用,而其他比例则可能是加和作用或拮抗作用。目前,脂质体、聚合物胶束、高分子囊泡、树枝状大分子、水凝胶和无机纳米粒子在内的纳米载体已被证明能成功地在各种肿瘤模型中共递送抗癌药物。这些纳米载体可改善药物的血清稳定性,提高生物相容性,延长在体内的循环时间。本文主要论述抗癌药物共递送原理、常见共递送载体类型以及CombiPlex平台完成临床试验的两种脂质体制剂和三类仍处于临床前研究的经典共递送系统,包括阿霉素和紫杉醇共递送系统、紫杉醇和顺铂共递送系统、阿霉素和姜黄素共递送系统,旨在为更多联合给药方案提供参考和新思路。
In recent years,the application of targeted nanotechnology has achieved good therapeutic effects in cancer treatment,especially the co-delivery of various anti-cancer drugs.Compared with single drug treatment,the combined application of different molecular targeted drugs has a wider treatment domain and effectively reduce adverse effects of drugs.In addition,the combination therapy of anti-cancer agents dependent on the same cell pathway decrease the dosage of each drug and enhance therapeutic effects.The aforementioned methods could reverse multi-drug resistance to a certain extent.However,combined administration is limited due to inconsistent cellular uptake caused by pharmacokinetic differences of different drugs.The therapeutic effects are closely related to the relative concentration of the combined drugs.A certain proportion of drug combinations could produce synergistic effect,while other proportions may be additive effect or antagonistic effect.At present,the nanocarriers,including liposomes,polymer micelles,polymer vesicles,dendrimers,hydrogels and inorganic nanoparticles have been demonstrated to deliver anti-cancer agents in various tumor models.These nanocarriers could improve serum stability,enhance biocompatibility and prolong in vivo circulation time.In the present review,we will highlight the co-delivery principle of anti-cancer drugs,the types of co-delivery carriers,two kinds of liposomes on the CombiPlex platform whose clinical trials have been completed,and three kinds of classical co-delivery drug systems that are still in preclinical research,including doxorubicin and paclitaxel co-delivery systems,paclitaxel and cisplatin co-delivery systems,doxorubicin and curcumin co-delivery systems.These emerging strategies promise reference and novel ideas for more combinatorial regimens.
作者
吴天怡
龚妍春
李资玲
李玉萍
熊向源
WU Tianyi;GONG Yanchun;LI Ziling;LI Yuping;XIONG Xiangyuan(School of Life Science,Jiangxi Science&Technology Normal University,Nanchang 330000,China)
出处
《材料导报》
EI
CAS
CSCD
北大核心
2020年第S01期516-522,共7页
Materials Reports
基金
国家自然科学基金(21664007)
江西省主要学科学术和技术带头人培养计划(20153BCB22009)
省级研究生创新专项资金(YC2019-S407)。
关键词
纳米药物
共递送
抗癌药物
多药耐药性
nanomedicine
co-delivery
anti-cancer agents
multi-drug resistance
